85021857 - AMT

Information

• Trademark
• 85021857

• Source

• Serial Number

  85021857

• Registration Number

  4017988

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  April 23, 2010
  14 years ago

• Registration Date

  August 30, 2011
  13 years ago

• Transaction Date

  May 15, 2018
  6 years ago

• Status Date

  April 06, 2018
  6 years ago

• Published for Opposition Date

  June 14, 2011
  13 years ago

• Location Date

  August 30, 2011
  13 years ago

• Status Code

  710

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  ERVIN, INGA MARIE

• Attorney Docket Number

  22572/17

  Attorney Name

  Mark S. Leonardo

  Law Office Assigned Location Code

  M20

• Owners

  • AMSTERDAM MOLECULAR THERAPEUTICS (AMT) IP B.V

Case File Statements

• GS0011: Nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cell transformed by viral vectors, gene therapy vectors and nucleic acid delivery vectors for other than medical and veterinary purposes; chemical reagents for scientific or research use, namely, nucleic acids and vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes
• GS0051: Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and call therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders, single gene disorders and cancers; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers
• GS0421: Laboratory research in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry; product development and consultancy in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry
• PM0000: AMERDAM MOLECULAR THERAPEUTICS

Case File Event Statements

• 4/6/2018 - 6 years ago

  23 - CANCELLED SEC. 8 (6-YR) Type: C8..

• 8/30/2011 - 13 years ago

  22 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 6/14/2011 - 13 years ago

  21 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 6/14/2011 - 13 years ago

  20 - PUBLISHED FOR OPPOSITION Type: PUBO

• 5/7/2011 - 13 years ago

  19 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 5/2/2011 - 13 years ago

  18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 4/13/2011 - 13 years ago

  17 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 4/13/2011 - 13 years ago

  16 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 4/13/2011 - 13 years ago

  15 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 2/3/2011 - 13 years ago

  14 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 2/3/2011 - 13 years ago

  13 - NON-FINAL ACTION E-MAILED Type: GNRT

• 2/3/2011 - 13 years ago

  12 - NON-FINAL ACTION WRITTEN Type: CNRT

• 1/11/2011 - 13 years ago

  11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 1/11/2011 - 13 years ago

  10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 1/11/2011 - 13 years ago

  9 - ASSIGNED TO LIE Type: ALIE

• 12/21/2010 - 14 years ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 6/22/2010 - 14 years ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 6/22/2010 - 14 years ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 6/22/2010 - 14 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 6/22/2010 - 14 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 5/1/2010 - 14 years ago

  3 - NOTICE OF PSEUDO MARK MAILED Type: MPMK

• 4/30/2010 - 14 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 4/27/2010 - 14 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP